| Literature DB >> 31579238 |
Mohsen Doostmohammadi1, Atefeh Ameri1, Reza Mohammadinejad1, Negar Dehghannoudeh2, Ibrahim M Banat3, Mandana Ohadi1, Gholamreza Dehghannoudeh1,4.
Abstract
Peptides are the most abundant biological compounds in the cells that act as enzymes, hormones, structural element, and antibodies. Mostly, peptides have problems to move across the cells because of their size and poor cellular penetration. Therefore, a carrier that could transfer peptides into cells is ideal and would be effective for disease treatment. Until now, plenty of polymers, e.g., polysaccharides, polypeptides, and lipids were used in drug delivery. Hydrogels made from polysaccharides showed significant development in targeted delivery of peptide hormones because of their natural characteristics such as networks, pore sizes, sustainability, and response to external stimuli. The main aim of the present review was therefore, to gather the important usages of the hydrogels as a carrier in peptide hormone delivery and their application in tissue engineering and regenerative medicine.Entities:
Keywords: drug delivery; hydrogels; peptides hormones; tissue engineering
Mesh:
Substances:
Year: 2019 PMID: 31579238 PMCID: PMC6770672 DOI: 10.2147/DDDT.S217211
Source DB: PubMed Journal: Drug Des Devel Ther ISSN: 1177-8881 Impact factor: 4.162
Using Strategies To Improve The Activity Of The PHs
| Type of PHs | Therapeutic Class | Instability Agents | Solution | Delivery Route | Ref. |
|---|---|---|---|---|---|
| Growth hormone | Physiological barriers: enzymes, mucus, and pH of the GI tract | Oral | |||
| Oral | |||||
| Oral | |||||
| Metal-catalyzed-oxidation (MCO) | Minimizing exposure to oxygen, by reducing the headspace in the vial | Oral | |||
| Deamidation-asparagine, glutamine | The pH value of the solution was reported to have an effect on the deamidation of Asn residues in hGH | Oral | |||
| Growth hormone | Iosmerization-Asparagine-X, Aspartic Acid-X | -Changes in temperature and pH buffer species-Ionic strength | Oral | ||
| Disulfide-scrambling/oligomerization cysteine | Changes in temperature and pH buffer species Ionic strength | Oral | |||
| Antiosteoporotic | Physiological barriers: enzymes, mucus, and pH of the GI tract | Oral | |||
| Oral | |||||
| Oral | |||||
| Antiosteoporotic | Physiological barriers: enzymes, mucus and pH of the GI tract | Citric acid, phenylethyl alcohol, benzyl alcohol, PEG sorbitan monooleate, to improve the biologicals absorption by the permeation enhancers | |||
| Nasal | |||||
| Oracal™ have the permeation enhancer and the coated vesicle in its structure | |||||
| Oral | |||||
| Regulating calcium ion concentration | β-Elimination | Changes in temperature and pH | Oral | ||
| High elimination rates of the drug in contact with its absorption sites | Oral | ||||
| Deamidation | The pH value of the solution was reported to have an effect on deamidation. pH 3–5, increased solvent viscosity | Oral | |||
| Oxidation | Deamidation reaction is dependent on varying pH values. The pH value (pH < 7) was significant in the reaction medium. Other factors, including air exclusion, antioxidants, chelating agents, and polyols affected oxidation | Oral | |||
| Aggregation/fibrillation | Lower concentration, minimal mechanical stress, organic solvents, alkyl saccharide, alkyl polyglycoside | Oral | |||
| Antidiabetic, hypoglycemic hormone | Physiological barriers: enzymes, mucus, and pH of the GI tract | Oral | |||
| Oral | |||||
| Oral | |||||
| Oral | |||||
| Buccal | |||||
| Antidiabetic, hypoglycemic hormone | Physiological barriers: enzymes, mucus and pH of the GI tract | Nasal | |||
| Peroral/Oral | |||||
| Peroral/Oral | |||||
| Insulin-containing multivesicular liposomes (MVLs), adding of novel chitosan and carbopol to MVLs as sustained release protein delivery systems | Oral | ||||
| Antidiabetic, hypoglycemic hormone | Oral | ||||
| Nasal; ocular | |||||
| Antidiabetic, hypoglycemic hormone | Physiological barriers: enzymes, mucus and pH of the GI tract | Oral | |||
| Oral capsule using non-acylated amino acids as carriers (Eligen™) | Oral | ||||
| Macrosol™ W/O (Water/Oil) microemulsion technology (Macrulin™) | Oral | ||||
| Oral formulation of recombinant human insulin (AI-401) | Oral | ||||
| Mixed micellar solution (Oral-lyn™) | |||||
| Deamidation | Deamidation reaction in peptides or proteins is pH-dependent | Oral | |||
| Isoelectric precipitation | Stresses such as temperature and moisture resulted in conformational changes, linear aggregation, and formation of a viscous gel | Oral | |||
| Antidiabetic, hypoglycemic hormone | Physiological barriers: enzymes, mucus and pH of the GI tract | To reduce degradation by enzymes and enhance absorption in the small intestine | Buccal | ||
| Oral | |||||
| Physiological barriers: enzymes, mucus and pH of the GI tract | Oral | ||||
| Antidiabetic, hypoglycemic hormone | Physiological barriers: enzymes, mucus and pH of the GI tract | Insulin analog NN1954, GIPET (GI permeation enhancement technology): To improve the biologicals absorption by the permeation enhancers | Intestine | ||
| Oral | |||||
| Anti-diabetic medication (type 2 diabetes mellitus) | Physiological barriers: enzymes, mucus and pH of the GI tract | Oral | |||
| Oral | |||||
| Oral | |||||
| Anti-diabetic medication (type 2 diabetes mellitus) | Physiological barriers: enzymes, mucus and pH of the GI tract | Oral | |||
Figure 1The PLGA-PEGPLGA hydrogel for controlled sCT release.
Note: Data from Liu et al.124